← Leaderboards
Monique Eun Hee Cho
Va Salt Lake City Healthcare System
$910,680
Attributed
$910,680
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $308K · FY2018–24$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$910,680 · 1
VA$0 · 1
By mechanism
R01$910,680 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Va Salt Lake City Healthcare System
Same institution · by research overlap
- Kalani Lukela Raphael$1,837,391
- Josef Stehlik$0
Others in their field
Other Emerging Leaders on “Mitochondria”
- Russell T Hepple · California Pacific Med Ctr Res Institute$13,797,603
- James Dale Berry · Brigham And Women'S Hospital$9,298,517
- Jennifer Cohen Price · University Of California, San Francisco$9,197,178
- Ansuman Satpathy · Stanford University$7,721,054
- Toren Finkel · Heart, Lung, And Blood Institute$6,457,574
- Zhen Zhao · University Of Southern California$6,254,766
Research focus
MitochondriaSafetyHeart FailureMetabolicPreventOralDiabeticHeartInsulin ResistanceMediatingEnd Stage Renal FailureMortalityCardiovascular DiseasesNational Institute Of Diabetes And Digestive And Kidney DiseasesCardiovascular Risk FactorCardiovascular SystemFutureGeneral PopulationClinical TrialsHomeostasisDiabetes MellitusKidneyDialysis ProcedureMyocardium
Grant awards (10)
Safety, tolerability, and feasibility of empagliflozin therapy in dialysis-dependent ESKD$295,680
R01 · FY2024 · DK · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2024 · VA · contact PI
Safety, tolerability, and feasibility of empagliflozin therapy in dialysis-dependent ESKD$308,000
R01 · FY2023 · DK · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2023 · VA · contact PI
Safety, tolerability, and feasibility of empagliflozin therapy in dialysis-dependent ESKD$307,000
R01 · FY2022 · DK · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2022 · VA · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2021 · VA · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2020 · VA · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2019 · VA · contact PI
The role of functional iron deficiency in systemic complications of CKD$0
I01 · FY2018 · VA · contact PI